Media
The following information is intended as a resource for journalists only and was factually correct at the time it was issued. For up to date safety information please refer to current consumer medicine information and product information.
For media-related enquiries, please contact
Corporate Communications
Australia and New Zealand
[email protected]
-
MAVIRET® (glecaprevir/pibrentasvir) registered in Australia for acute hepatitis C virus infection
-
AbbVie set to move office to Sydney CBD in 2026
-
AbbVie welcomes PBS listing of VYALEV®
-
Australians want more investment in the PBS
-
AbbVie Australia celebrates 12 years of Great Place to Work® certification
-
AbbVie appoints Dr Carly Levetan as Associate Medical Director, Oncology
-
AbbVie appoints Sarah Bridge as Market Access Director, ANZ
-
AbbVie australia leadership credits employees for 11th consecutive year of Best Workplaces list ranking
-
Half of australians live with chronic health conditions, over a third forced to leave their jobs as a result
-
Inflammatory bowel disease experts call for urgent action to ensure equitable, multidisciplinary care in australia as prevalence continues to rise
-
AbbVie celebrates recognition as leader in workplace gender equity
Unless otherwise specified, all product names appearing in this internet site are trademarks owned by or licensed to AbbVie Inc., its subsidiaries or affiliates. No use of any AbbVie trademark, trade name, or trade dress in this site may be made without the prior written authorization of AbbVie Inc., except to identify the product or services of the company.
AbbVie acknowledges the Traditional Custodians of Country throughout Australia and their continuing connection to land, waters and community. We pay our respect to them and their cultures, and Elders, past and present.
Copyright © 2026 AbbVie Inc. North Chicago, Illinois, U.S.A.
